Catalyst Pharmaceutical
CPRX
49 hedge funds and large institutions have $25.4M invested in Catalyst Pharmaceutical in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 18 reducing their positions, and 15 closing their positions.
41% more capital invested
Capital invested by funds: $18M → $25.4M (+$7.4M)
21% less funds holding
Funds holding: 62 → 49 (-13)
61% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 18
87% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 15
Top Buyers
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$298K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$253K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$200K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
-$168K |
| 5 |
Millennium Management
New York
|
-$153K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DS
51
DRW Securities
Chicago,
Illinois
| – | -$168K | -237,200 | Closed |
|
|
OAM
52
Oxford Asset Management
Oxford,
United Kingdom
| – | -$128K | -180,721 | Closed |
|
|
ARTA
53
A.R.T. Advisors
New York
| – | -$89K | -126,289 | Closed |
|
|
LP
54
LMR Partners
London,
United Kingdom
| – | -$79K | -112,476 | Closed |
|
|
AGM
55
Alpine Global Management
New York
| – | -$73K | -102,782 | Closed |
|
56
Jane Street
New York
| – | -$47K | -65,594 | Closed |
|
57
UBS Group
Zurich,
Switzerland
| – | -$38K | -53,536 | Closed |
|
58
Squarepoint
New York
| – | -$29K | -41,400 | Closed |
|
59
D.E. Shaw & Co
New York
| – | -$23K | -33,094 | Closed |
|
|
AFG
60
Albion Financial Group
Salt Lake City,
Utah
| – | -$18K | -24,800 | Closed |
|
61
New York State Common Retirement Fund
Albany,
New York
| – | -$15K | -20,600 | Closed |
|
|
WS
62
Wedbush Securities
Los Angeles,
California
| – | -$12K | -17,000 | Closed |
|
|
VKH
63
Virtu KCG Holdings
New York
| – | -$9K | -12,865 | Closed |
|
64
Barclays
London,
United Kingdom
| – | -$6K | -7,986 | Closed |
|
CPRX Hedge Fund Activity: Q3 2016 in Review
49 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2016, worth a combined $25.4M — up 41% from $18M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CPRX and 2 opened new positions — a net loss of 13 holders — while 18 trimmed existing stakes and 7 added.
The largest buyer was GSA Capital Partners, adding an estimated $113K. The largest seller was Deutsche Bank, cutting an estimated $298K.
- 49 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2016, down from 62 in Q2 2016.
- Funds reported $25.4M of Catalyst Pharmaceutical stock for Q3 2016, up 41% quarter-over-quarter.
- 2 funds opened new Catalyst Pharmaceutical positions in Q3 2016 and 15 closed out, a net change of -13 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2016 was GSA Capital Partners, an estimated $113K added.
- The largest Catalyst Pharmaceutical seller in Q3 2016 was Deutsche Bank, an estimated $298K sold.
Based on aggregated 13F filings for Q3 2016.